TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05798780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE Intervention - Exercise and Nutrition
Description: During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENHANCE Intervention - Nutrition Only
Description: During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
Study: NCT06001684

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBR854 Cell Injection
Description: The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
Study: NCT06188260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane COMPLETE Lubricant Eye Drops
Description: Active Ingredients: Propylene Glycol 0.6% Purpose: Lubricant
Study: NCT05854628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Skin biopsies will be obtained at different time points.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin biopsy
Description: Skin biopsies will be obtained at different time points.
Study: NCT06280729

Intervention type: OTHER
Intervention: AI-Analyis
Description: The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).

Intervention type: OTHER
Intervention: AI-Analyis
Description: The study will investigate classification (ie logistic regression, decision tree, random forest, support vector machine, K nearest neighbour, naive bayes) ML models and treatment effect estimation ML models (T-learner, X-learner..).
Study: NCT06090357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar pressure
Description: Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
Study: NCT05989737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Enhanced Behavior Therapy
Description: 8-module intervention delivering acceptance-enhanced behavior therapy through a fully automated website. This intervention was adapted from the Acceptance-enhanced behavior therapy workbook (Woods \& Twohig, 2008).
Study: NCT06041672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm Water Hand Baths
Description: 1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position.
Study: NCT05793099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of aqueous propolis gums in salivary and dental plaque pH in children
Description: The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given aqueous propolis gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing aqueous propolis gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effect of placebo gums in salivary and dental plaque pH in children
Description: The child will be given a 10% sucrose solution, and the salivary pH will be measured before and after giving sucrose solution (Baseline) and then the child will be given placebo gum to chew for 15 minutes to stimulate salivation. The saliva pH will be measured by taking a sample of the patient's saliva (3ml) while chewing the gum in the mouth in a disposable container and then saliva pH will be measured.~Dental plaque pH also will be measured before and after administration of a 10% sucrose solution (Baseline), and then 15 minutes after chewing placebo gum dental plaque will be collected using the plaque collection technique from the 6 buccal surfaces of teeth 16,21,26,36,41,46 using a sterile excavator. The sample will be mixed with 0.05 ml of distilled water until it dissolves and then dental plaque pH will be measured.
Study: NCT04812483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag (Revolade®)
Description: Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.

Intervention type: DRUG
Group type: OTHER
Intervention: standard therapy (without eltrombopag): HD-DXM
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy (without eltrombopag): HD-DXM
Description: standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
Study: NCT05933603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine and Oxybutynin (ato-oxy)
Description: 0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
Study: NCT06239753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization
Description: Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Prenatal Education Program Implementation
Description: Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
Study: NCT06098261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Bilastine
Description: Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test (T) Bilastine
Description: Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
Study: NCT04749667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSCs
Description: Autologous bone-marrow derived mesenchymal stem cells
Study: NCT04787809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well
Description: Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
Study: NCT06439706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling
Description: HPV self-sampling kit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Self-Sampling
Description: HPV self-sampling kit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Education
Description: Small-group education led by bilingual health educator
Study: NCT04749667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSCs
Description: Autologous bone-marrow derived mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Isotonic saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Isotonic saline
Study: NCT04973696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolkit for Optimal Recovery after Orthopedic Injury
Description: The Toolkit (TOR) is a 4-session, individual, live video, synchronous program developed specifically for patients with orthopedic acute injuries who are at risk for chronic pain and disability. The program teaches evidence-based mind-body skills (e.g., relaxation and mindfulness; myths about pain; activity pacing; acceptance and values based goal setting). Participants gain access to a website downloaded on their phones as an app. The website included explainer videos of skills and recordings of mindfulness and relaxation exercises. In addition, participants will receive usual care as determined by medical team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEUC)
Description: The MEUC is educational material, in the form of a physical hard-copy pamphlet and website downloaded as an app on their phones. In addition, participants will receive usual care as determined by medical team.
Study: NCT05232981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation of the bilateral internal iliac arteries
Description: opening the posterior peritoneum overlying the bifurcation of the common iliac arteries. Then careful dissection of the internal iliac artery is carried out on each side and the anterior division of the internal iliac artery is ligated 4 cm below the bifurcation of the common iliac on both sides by single ligation procedure using Vicryl 1.0 .~Re-checking of the femoral pulsation of both sides is performed. Then, the placenta is removed manually in a piecemeal manner, any remaining bleeding points from the placental site are then controlled by hemostatic sutures .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shehat's technique
Description: The three-step technique (Shehata's technique) entailed 3 steps, the first step is double bilateral ligation of uterine arteries before placental separation. Uterine artery ligation is made at 2 levels. First will be done at the isthmus and second will be done 1 cm above the cesarean incision. Regarding timing of ligation , we will apply the uterine artery ligation before placental separation to minimize blood loss at the attempt of placental separation.~Placenta is separated manually either totally or in piecemeal. If manual separation failed, placenta is removed by scissors.~Application of quadruple sutures is done at the lower uterine segment to compress and secure the neovascularization in the bed of placenta.~Insertion of triple way catheter is commenced from inside the uterine incision downwards using long artery forceps or uterine sound and the pulled by the assistant from below. The catheter balloon is inflated by 50 cc saline and left for 48 hours
Study: NCT05292963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention #1: Fatherhood Works Program Delivered to Participants
Description: Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person. Participants also receive employment supports, case management, and financial literacy training.
Study: NCT04792515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with SOX/ or apatinib
Description: Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing.
Study: NCT06098261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Bilastine
Description: Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference (R) Bilastine
Description: Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
Study: NCT05379868

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior column osteotomy
Description: Apical full facet joint resection. Study intervention does not involve a device.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No osteotomies
Description: Standard treatment
Study: NCT06630312

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha galactosidase
Description: Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha galactosidase
Description: Alpha galactosidase capsule, 600 GALU, manufacturer Equate brand, Walmart. Powder contents from one capsule were stirred into 16 g spaghetti sauce and served before the main meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 16 gm of spaghetti sauce served before the meal in a condiment cup. It is the same set up as the intervention except the \&#39;intervention\&#39; contains the AGS.
Study: NCT06268301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide oral suspension
Study: NCT02028975

Intervention type: OTHER
Group type: OTHER
Intervention: Measure the threshold of detection for linoleic acid

Intervention type: OTHER
Group type: OTHER
Intervention: Measure the threshold of detection for linoleic acid

Intervention type: OTHER
Group type: OTHER
Intervention: Measure the threshold of detection for linoleic acid

Intervention type: OTHER
Group type: OTHER
Intervention: Oral stimulation tests

Intervention type: OTHER
Group type: OTHER
Intervention: Oral stimulation tests

Intervention type: OTHER
Group type: OTHER
Intervention: Oral stimulation tests

Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Samples for genetic studies (ancillary study)

Intervention type: OTHER
Group type: OTHER
Intervention: Samples for genetic studies (ancillary study)

Intervention type: OTHER
Group type: OTHER
Intervention: Samples for genetic studies (ancillary study)
Study: NCT05446389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier Activated Lullaby ®
Description: Pacifier Activated Lullaby (PAL®) is a medical device that encourages and reinforces the development of non-nutritive sucking (NNS) of premature infants. This is accomplished by giving positive feedback in the form of music/mother's voice as an auditory input in direct response to effective sucking.
Study: NCT04944095

Intervention type: OTHER
Intervention: Change in SARS-CoV-2 Antibody Levels
Description: Changes in plasma antibody levels over 12 months will be determine post-vaccination with one of the authorized SARS-CoV-2 vaccines.
Study: NCT05216003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH4YOU
Description: PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
Study: NCT01069614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopClosure 3S System
Study: NCT05579288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O/O2)
Description: Nitrous oxide (N2O/O2) for pain alleviation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (O2)
Description: Oxygen (O2) as placebo for control group
Study: NCT03733535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
Study: NCT06398834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butorphanol
Description: In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
Study: NCT03733535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129 Xenon
Description: 1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
Study: NCT06460662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physical Therapy
Description: Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques
Study: NCT06297902

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose painting
Description: Dose painting
Study: NCT05629572

Intervention type: DIAGNOSTIC_TEST
Intervention: i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity
Description: Paired whole blood and plasma samples collected at multiple time points.
Study: NCT06569940

Intervention type: DEVICE
Group type: OTHER
Intervention: Sleepiz One+
Description: In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
Study: NCT06487078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK-positive NSCL treatment
Study: NCT05843162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
Study: NCT05942859

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence and Machine Learning technology
Description: Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial Intelligence and Machine Learning technology
Description: Artificial Intelligence describes computer software designed to mimic human cognitive function. Machine learning is a type of artificial intelligence in which the model created is exposed to data, identifies patterns, and recognises relationships between features seen in the data and the 'ground truth'. This technology will be applied to participants ECGs.
Study: NCT05653726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring follow-up using medical devices and telematic consultations
Description: Home telemonitoring of blood pressure, heart rate and peripheral oxygen saturation on a daily basis during 12 months